Compass Therapeutics Inc.
NASDAQ:CMPX
Compass Therapeutics Inc.
Total Equity
Compass Therapeutics Inc.
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Compass Therapeutics Inc.
NASDAQ:CMPX
|
Total Equity
$209.6m
|
CAGR 3-Years
22%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
-$2.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$22.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$8.7B
|
CAGR 3-Years
33%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-11%
|
|
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
Total Equity
$233.3m
|
CAGR 3-Years
27%
|
CAGR 5-Years
36%
|
CAGR 10-Years
15%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$18.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
17%
|
CAGR 10-Years
35%
|
|
Compass Therapeutics Inc.
Glance View
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-11-13. Its pipeline of product candidates includes both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed for anti-tumor response to cancer. Its lead product candidate, CTX-471, is a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells. Its second product candidate, CTX-8371, is a bispecific antibody that simultaneously targets both PD-1 and PD-L1, the targets of checkpoint inhibitor antibodies. In addition to CTX-471 and CTX-8371, It is also developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. Its product candidate, CTX-009, is an anti-DLL4 x VEGF-A bispecific antibody, which has added to its pipeline through Trigr Therapeutics, Inc. (TRIGR).
See Also
What is Compass Therapeutics Inc.'s Total Equity?
Total Equity
209.6m
USD
Based on the financial report for Sep 30, 2025, Compass Therapeutics Inc.'s Total Equity amounts to 209.6m USD.
What is Compass Therapeutics Inc.'s Total Equity growth rate?
Total Equity CAGR 5Y
35%
Over the last year, the Total Equity growth was 51%. The average annual Total Equity growth rates for Compass Therapeutics Inc. have been 22% over the past three years , 35% over the past five years .
